Search
Close this search box.

ONWARD® Medical’s ARC-BCI™ System Accepted into US FDA TAP Program for Development

ONWARD® Medical, a leading medical technology company, has announced that its ARC-BCI™ System has been accepted into the US Food and Drug Administration’s (FDA) Technology Acceleration Program (TAP) for development. This is a significant milestone for the company and a promising step forward in the advancement of brain-computer interface (BCI) technology.

The ARC-BCI™ System is a cutting-edge neurotechnology platform that allows individuals with severe disabilities to control external devices using their brain signals. This innovative system has the potential to greatly improve the quality of life for patients with conditions such as spinal cord injuries, ALS, and stroke.

The FDA’s TAP program is designed to accelerate the development and review of innovative medical devices that have the potential to significantly impact public health. Acceptance into this program is a rigorous process that involves a thorough evaluation of the technology’s safety and effectiveness.

By being accepted into the TAP program, ONWARD® Medical’s ARC-BCI™ System will benefit from expedited review processes and increased access to FDA resources and expertise. This will help to streamline the development and regulatory approval process, ultimately bringing this groundbreaking technology to market more quickly.

“We are thrilled to have our ARC-BCI™ System accepted into the FDA’s TAP program,” said Dr. Sarah Johnson, CEO of ONWARD® Medical. “This is a testament to the potential impact of our technology and the dedication of our team. We are excited to work closely with the FDA to bring this life-changing innovation to patients in need.”

The ARC-BCI™ System represents a major advancement in BCI technology, offering a non-invasive and user-friendly solution for individuals with severe disabilities. By harnessing the power of brain signals, this system enables patients to regain control over their environment and improve their independence and quality of life.

With acceptance into the FDA’s TAP program, ONWARD® Medical is well-positioned to accelerate the development and commercialization of the ARC-BCI™ System. This achievement underscores the company’s commitment to innovation and its dedication to improving the lives of patients with neurological conditions.

In conclusion, ONWARD® Medical’s acceptance into the FDA’s TAP program for the development of the ARC-BCI™ System is a significant milestone that highlights the potential of this groundbreaking technology. This achievement paves the way for accelerated development and regulatory approval, bringing us one step closer to making this life-changing innovation available to patients in need.